Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific MeetingGlobeNewsWire • Thursday
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetGlobeNewsWire • 10/08/26
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in TherapyGlobeNewsWire • 10/05/26
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial WinSeeking Alpha • 09/09/26
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema TranscriptSeeking Alpha • 09/08/26
Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record HighsInvestors Business Daily • 09/08/26
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE AttacksGlobeNewsWire • 09/08/26
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026GlobeNewsWire • 09/03/26
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/12/26
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in ImmunologyGlobeNewsWire • 08/06/26
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a BetZacks Investment Research • 07/31/26
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated AngioedemaGlobeNewsWire • 07/22/26
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to BuyZacks Investment Research • 07/15/26
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to TradeZacks Investment Research • 07/14/26
Why This Biotech, Up 14% Since Its Breakout, Is On The Rise Once AgainInvestors Business Daily • 07/06/26
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema AttacksGlobeNewsWire • 07/06/26
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026GlobeNewsWire • 06/15/26